Trial 2O-17-1


PhII-151 A Phase II Study of Olaparib plus Cediranib in Combination with Standard Therapy for Small Cell Lung Cancer

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Anti-Angiogenesis, Chemotherapy: Systemic
Randomized: Yes
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Ramona Lujan, Coordinator, Lusine Raddatz, D.M., Victoria Amran, D.M., Grace Facio, Coordinator, Charlean Ketchens, Coordinator, Gina Tse, Coordinator, Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator, Bartolo Santos, Coordinator, Peter Alexander, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.